Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy

Lung Cancer

Volumn 78, Issue 1, 2012, Pages 23-29

  Fischer, Bruno ^a   Frei, Claudia ^a   Moura, Ubiratan ^a   Stahel, Rolf ^a   Felley Bosco, Emanuela ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

ABCG2 transporter; Chemoresistance; Drug efflux; Mesothelioma; Mitoxantrone; Pemetrexed; PI3 kinase signaling

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; BREAST CANCER RESISTANCE PROTEIN; FUMITREMORGIN C; INITIATION FACTOR 4E BINDING PROTEIN 1; MITOXANTRONE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; S6 KINASE; WORTMANNIN;

ARTICLE; CANCER CELL CULTURE; CYTOTOXICITY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PHENOTYPE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CELL MEMBRANE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GLUTAMATES; GUANINE; HUMANS; IMIDAZOLES; MESOTHELIOMA; MITOXANTRONE; NEOPLASM PROTEINS; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; PLEURAL NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINOLINES; SIDE-POPULATION CELLS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84866184583     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.07.005     Document Type: Article

References (36)

1. Fennell D.A., Rudd R.M. Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. Lancet Oncol 2004, 5:354-362.
2. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-284.
3. Frei C., Opitz I., Soltermann A., Fischer B., Moura U., Rehrauer H., et al. Pleural mesothelioma side populations have a precursor phenotype. Carcinogenesis 2011, 32:1324-1332.
4. Goodell M.A. Multipotential stem cells and 'side population' cells. Cytotherapy 2002, 4:507-508.
5. Szakacs G., Annereau J.P., Lababidi S., Shankavaram U., Arciello A., Bussey K.J., et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004, 6:129-137.
6. Mogi M., Yang J., Lambert J.F., Colvin G.A., Shiojima I., Skurk C., et al. Akt signaling regulates side population cell phenotype via Bcrp1 translocation. J Biol Chem 2003, 278:39068-39075.
7. Takada T., Suzuki H., Gotoh Y., Sugiyama Y. Regulation of the cell surface expression of human BCRP/ABCG2 by the phosphorylation state of Akt in polarized cells. Drug Metab Dispos 2005, 33:905-909.
8. Hu C., Li H., Li J., Zhu Z., Yin S., Hao X., et al. Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis 2008, 29:2289-2297.
9. Zhou J., Wulfkuhle J., Zhang H., Gu P., Yang Y., Deng J., et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA 2007, 104:16158-16163.
10. Bleau A.M., Hambardzumyan D., Ozawa T., Fomchenko E.I., Huse J.T., Brennan C.W., et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009, 4:226-235.
11. Liu T.J., Koul D., LaFortune T., Tiao N., Shen R.J., Maira S.M., et al. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 2009, 8:2204-2210.
12. Chiarini F., Grimaldi C., Ricci F., Tazzari P.L., Evangelisti C., Ognibene A., et al. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res 2010, 70:8097-8107.
13. Maira S.M., Stauffer F., Brueggen J., Furet P., Schnell C., Fritsch C., et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008, 7:1851-1863.
14. Schmitter D., Lauber B., Fagg B., Stahel R.A. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer 1992, 51:296-301.
15. Ozvegy-Laczka C., Varady G., Koblos G., Ujhelly O., Cervenak J., Schuetz J.D., et al. Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface. J Biol Chem 2005, 280:4219-4227.
16. Robey R.W., Medina-Perez W.Y., Nishiyama K., Lahusen T., Miyake K., Litman T., et al. Overexpression of the ATP-binding cassette half-transporter ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 2001, 7:145-152.
17. Li L., Sham Y.Y., Bikadi Z., Elmquist W.F. pH-Dependent transport of pemetrexed by breast cancer resistance protein. Drug Metab Dispos 2011, 39:1478-1485.
18. Mikami I., Zhang F., Hirata T., Okamoto J., Koizumi K., Shimizu K., et al. Inhibition of activated phosphatidylinositol 3-kinase/AKT pathway in malignant pleural mesothelioma leads to G1 cell cycle arrest. Oncol Rep 2010, 24:1677-1681.
19. Robey R.W., To K.K., Polgar O., Dohse M., Fetsch P., Dean M., et al. ABCG2: a perspective. Adv Drug Deliv Rev 2009, 61:3-13.
20. Fan Q.W., Cheng C.K., Nicolaides T.P., Hackett C.S., Knight Z.A., Shokat K.M., et al. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 2007, 67:7960-7965.
21. Brunner-Kubath C., Shabbir W., Saferding V., Wagner R., Singer C.F., Valent P., et al. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Res Treat 2011, 129:387-400.
22. Altomare D.A., You H., Xiao G.H., Ramos-Nino M.E., Skele K.L., De Rienzo A., et al. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 2005, 24:6080-6089.
23. Cedres S., Montero M.A., Martinez P., Martinez A., Rodriguez-Freixinos V., Torrejon D., et al. Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). Lung Cancer 2012.
24. Campbell N.P., Kindler H.L. Update on malignant pleural mesothelioma. Semin Respir Crit Care Med 2011, 32:102-110.
25. van Meerbeeck J.P., Scherpereel A., Surmont V.F., Baas P. Malignant pleural mesothelioma: the standard of care and challenges for future management. Crit Rev Oncol Hematol 2011, 78:92-111.
26. Opitz I., Soltermann A., Abaecherli M., et al. PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg 2008, 33:502-506.
27. Carracedo A., Alimonti A., Pandolfi P.P. PTEN level in tumor suppression: how much is too little?. Cancer Res 2011, 71:629-633.
28. Leslie N.R., Foti M. Non-genomic loss of PTEN function in cancer: not in my genes. Trends Pharmacol Sci 2011, 32:131-140.
29. Thomas R.K., Baker A.C., Debiasi R.M., Winckler W., Laframboise T., Lin W.M., et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007, 39:347-351.
30. Bott M., Brevet M., Taylor B.S., Shimizu S., Ito T., Wang L., et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011, 43:668-672.
31. Hoang C.D., Zhang X., Scott P.D., Guillaume T.J., Maddaus M.A., Yee D., et al. Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes. Cancer Res 2004, 64:7479-7485.
32. Xia X., Yang J., Li F., Li Y., Zhou X., Dai Y., et al. Image-based chemical screening identifies drug efflux inhibitors in lung cancer cells. Cancer Res 2010, 70:7723-7733.
33. Yoh K., Ishii G., Yokose T., Minegishi Y., Tsuta K., Goto K., et al. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 2004, 10:1691-1697.
34. Brevet M., Shimizu S., Bott M.J., Shukla N., Zhou Q., Olshen A.B., et al. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy. J Thorac Oncol 2011, 6:864-874.
35. Ou W.B., Hubert C., Corson J.M., Bueno R., Flynn D.L., Sugarbaker D.J., et al. Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma. Neoplasia 2011, 13:12-22.
36. Sekido Y. Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation. Pathol Int 2011, 61:331-344.